Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CMKLR1 antagonistic polypeptide and derivative and application thereof

A derivative, antagonistic technology used in biotechnology and biomedicine

Active Publication Date: 2019-06-28
SHENZHEN INST OF ADVANCED TECH
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As CMKLR1 is one of the members of GPCRs, there is still no drug that directly targets CMKLR1 to treat clinical cancer.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CMKLR1 antagonistic polypeptide and derivative and application thereof
  • CMKLR1 antagonistic polypeptide and derivative and application thereof
  • CMKLR1 antagonistic polypeptide and derivative and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0096] Example 1: Panning, amplification, purification, sequencing and synthesis of CMKLR1 antagonistic polypeptide LRH7-C2.

[0097] This example is mainly for the purpose of screening positive phages that specifically bind to CMKLR1, and then by amplifying and purifying the positive phages, extracting phage single-stranded DNA (ssDNA) for sequencing, analyzing and comparing the obtained sequences, and finally synthesizing high-purity The antagonistic polypeptide LRH7-C2.

[0098] details as follows:

[0099] 1. Establishment of 293T cell line with permanent high expression of CMKLR1: 293T-CMKLR1 + / + / LRH

[0100] ①Select vigorously growing luminescent human 293T cells, and the day before transfection, use 5×10 5 cells / well, inoculated in a 6-well plate, cultured until the second day, the cell fusion degree was 60%;

[0101] ② Transfect on the second day, take one culture well of a 6-well plate as a unit, dilute 3 μg of plasmid with 200 μL of opti-MEM medium, and dilute 6...

Embodiment 2

[0118] Example 2 The CMKLR1 antagonistic polypeptide LRH7-C2 can effectively promote the inhibitory effect of chemerin on the cAMP signaling pathway.

[0119] (1) Cyclic adenosine monophosphate (cAMP) ELISA:

[0120]① Cell plating: Wild-type 293T cells and 293T cells highly expressing CMKLR1 (293TCMKLR1 + / + ), with 5ⅹ10 5 Each well was inoculated in a 6-well cell culture plate, the volume of each well was 1 mL, placed in an incubator for 24 hours, starved overnight, and LRH7-C2 polypeptides with different concentration gradients (3 μM, 0.3 μM, 0.03 μM) were added , Fosklin (25μM) and chemerin (30nM) for 6h;

[0121] ②Sample preparation: Add 300 μL of cell lysate to each well, place at 4°C for 20 minutes, scrape and collect cells with a cell scraper, mix them upside down, centrifuge at 12,000 rpm for 10 minutes, and collect the supernatant;

[0122] ③ Determination of sample concentration: the sample concentration is determined by BCA method;

[0123] ④ Cyclic adenosine mon...

Embodiment 3

[0130] Example 3 CMKLR1 antagonistic polypeptide LRH7-C2 can effectively inhibit calcium (Ca 2+ ) inflow effect.

[0131] ① Cell plating: Wild-type 293T cells and 293T cells highly expressing CMKLR1 (293T CMKLR1 + / + ), with 5ⅹ10 3 Each cell / well was inoculated in a 96-well cell culture plate, the volume of medium in each well was 200 μL, placed in an incubator for 24 hours, and then starved overnight;

[0132] ②Reagent configuration: dissolve probenecid into 1mL buffer solution to prepare probenecid with a concentration of 250nM, shake well, add to fluorescent reagent for use;

[0133] ③Remove the cell culture medium, add LRH7-C2 polypeptide and chemerin (0.3nM) with different concentration gradients (30 μM, 3 μM, 0.3 μM, 0.03 μM, 0.003 μM) for 30 minutes, and then add 100 μL of the above fluorescent reagent to each well;

[0134] ④ Place at 37°C for 30 minutes, then at room temperature for 30 minutes;

[0135] ⑤Measure the fluorescence absorbance at excitation light 494nm...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CMKLR1 antagonistic polypeptide and a derivative and application thereof and particularly relates to a CMKLR1 antagonistic polypeptide shown in SEQ ID No.1-9 and a derivativethereof. The derivative of the binding peptide is a product obtained in the mode that conventional modification is conducted on a CMKLR1 binding peptide amino acid side chain group and an amino terminal or a carboxyl terminal of a CMKLR1 antagonistic polypeptide fragment or a product obtained in the mode that a label for detection or purification of polypeptide or protein is linked to the CMKLR1antagonistic polypeptide. The binding peptide and the derivative thereof can be combined with CMKLR1 in vitro, by stopping combination of chemerin / RvE1 and CMKLR1, the cAMP concentration is changed, the calcium influx caused by chemerin and cell chemotaxis caused by chemerin are inhibited, and effective micromolecule treatment drugs are provided for diseases of high-expression CMKLR1 receptors.

Description

technical field [0001] The present invention relates to the field of biotechnology and biomedicine, specifically, the present invention is the female reproductive disease target CMKLR1 receptor antagonizing polypeptide LRH7-C2 and its derivatives and applications. Background technique [0002] Among female reproductive cancers, some are related to endocrine. For example, breast cancer (Breast Cancer), endometrial cancer (Endometrial Cancer) and ovarian cancer (Ovarian Cancer, OAC), etc. Among them, ovarian cancer is a malignant tumor that occurs in the ovary, 90% to 95% are primary ovarian cancers, and the other 5% to 10% are primary cancers in other parts that have metastasized to the ovary. Although the incidence of ovarian cancer in my country is not as high as that in Europe and the United States, radical surgery and cytotoxic chemotherapy are not effective in reducing the mortality of ovarian cancer. Due to lack of symptoms in the early stage of ovarian cancer, even i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06C12N15/11A61K38/08A61P35/00A61P29/00A61P1/16A61P3/10
Inventor 张键代小勇余贵媛蔡佳璇薛丽汪宝蓓
Owner SHENZHEN INST OF ADVANCED TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com